Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
41.12 USD +2.17% Intraday chart for Bristol-Myers Squibb Company -0.28% -19.85%
02:00pm Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE
02:00pm GSK blood cancer drug nearly halves risk of death in late-stage trial RE

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
RE
GSK blood cancer drug nearly halves risk of death in late-stage trial
RE
US FDA allows use of Bristol's cell therapy for rare blood cancer
RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval
MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer
MT
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine
CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License
MT
Bristol Myers: will present data on schizophrenia
CF
Bristol Myers: presents over 130 studies at ASCO
CF
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment
MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines
MT
Bristol Myers: 10-year strategy for poor countries
CF
Bristol-Myers Squibb Invests in NeoPhore
MT
Bristol Myers: national schizophrenia campaign
CF
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (Nivolumab and Hyaluronidase)
CI
Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis
CI
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
CI
US FDA approves expanded use of Bristol's cancer cell therapy
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Highlights